期刊
AMERICAN JOURNAL OF CARDIOLOGY
卷 110, 期 9, 页码 43B-49B出版社
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2012.08.033
关键词
-
资金
- Novo Nordisk Inc.
- Amgen
- AstraZeneca
- Merck
- Sanofi-Aventis
In patients with diabetes mellitus (DM), a cardiovascular event is of critical concern because of the impact on long-term survival. Cardiovascular disease (CVD) is the leading cause of death for patients with DM, which makes the modification of risk factors in the patient with DM and CVD a primary focus of the preventive cardiologist. Management of this patient population should include pharmacologic interventions, such as antidyslipidemics (mainly statins) and oral anti-DM (or insulin) agents, as well as diet control, physical exercise, and smoking cessation. It is hoped that focus on the ABCs of treatment-hemoglobin A(1c), blood pressure, and cholesterol-lipid profile-along with ongoing and future studies on the effects of these interventions will help to reduce the significant morbidity and mortality from microvascular and macrovascular complications in these high-risk patients with DM. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110[suppl]:43B-49B)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据